NYSE · ABT
Abbott Laboratories
$104.57+$1.93 (+1.88%)
Abbott Laboratories’s quoted price sits in the lower half of its reported 52-week range, 20.8% below the high.
Loading market information…
NASDAQ · GEHC · USD
Stock price, dividends, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
GE HealthCare Technologies Inc.’s quoted price sits in the upper half of its reported 52-week range, 14.87% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
THE INCOME SIDE
GE HealthCare Technologies Inc.’s forward annual dividend is $0.16 per share, paid quarterly. The forward yield is 0.21% at the quoted price. Future payments can change.
Historical amounts are adjusted for stock splits. Understand ex-dividend and payment dates →
BEHIND THE RESULTS
GE HealthCare Technologies Inc.’s next earnings report is currently expected on Feb 3, 2027, with estimated earnings per share of $1.60. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow GE HealthCare Technologies Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
GE HealthCare Technologies Inc. is a global medical technology company that creates, manufactures, and markets a diverse range of medical devices, services, and integrated digital solutions. These offerings are designed to assist in the diagnosis, treatment, and ongoing monitoring of patients. The company boasts an extensive international presence, serving markets across the United States, Canada, Europe, the Middle East, Africa, China, Taiwan, Mongolia, and Hong Kong, among other regions. Its operations are structured across four primary business divisions: Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics. The Imaging division specializes in advanced diagnostic imaging technologies, including systems for molecular imaging, Computed Tomography (CT) scans, Magnetic Resonance (MR) imaging, image-guided therapy, and X-ray, alongside specialized women's health products. The Ultrasound segment delivers a comprehensive suite of ultrasound solutions utilized for the screening, diagnosis, treatment, and monitoring of various diseases. These applications span radiology, primary care, women's health, cardiovascular diagnostics, point-of-care, and portable handheld devices, in addition to products supporting surgical visualization and guidance. The Patient Care Solutions segment is dedicated to providing essential medical devices, consumable products, services, and digital platforms. Its portfolio encompasses patient monitoring, anesthesia delivery and respiratory care, diagnostic cardiology, and maternal-infant care products. The Pharmaceutical Diagnostics segment supplies specialized diagnostic agents to the radiology and nuclear medicine industries. These include contrast media pharmaceuticals, administered to patients prior to scans like CT, angiography, X-ray, and MR, to enhance the visibility of internal tissues and structures. It also offers molecular imaging agents, or radiopharmaceuticals – molecular tracers labeled with radioisotopes – injected into patients for advanced diagnostic imaging applications such as Single-Photon Emission Computed Tomography (SPECT), Positron Emission Tomography (PET), and specific ultrasound procedures. Established in 2022, GE HealthCare Technologies Inc. maintains its corporate headquarters in Chicago, Illinois.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 02:33 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
Completed calendar years and any current-year payments shown separately. Current-year totals are incomplete until all payments are made.
See annual income at the current dividend rate.
Assumes the annual dividend stays unchanged. Payments follow the company’s schedule. Excludes taxes, fees and currency changes.
| Q2 2025 | Jul 30, 2025 | $1.06+15.47% vs estimate | $5.01B+0.66% vs estimate |
|---|
| Q1 2025 | Apr 30, 2025 | $1.01+10.5% vs estimate | $4.78B+2.52% vs estimate |
|---|
| Q4 2024 | Feb 13, 2025 | $1.45+15.08% vs estimate | $5.32B-0.23% vs estimate |
|---|
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
KEEP COMPARING
$104.57+$1.93 (+1.88%)
Abbott Laboratories’s quoted price sits in the lower half of its reported 52-week range, 20.8% below the high.
$97.11+$2.33 (+2.46%)
Medtronic Plc’s quoted price sits in the upper half of its reported 52-week range, 8.67% below the high.
$311.36+$7.36 (+2.42%)
Stryker Corporation’s quoted price sits in the lower half of its reported 52-week range, 20.03% below the high.
$42.69+$0.26 (+0.61%)
Boston Scientific Corporation’s quoted price sits in the lower half of its reported 52-week range, 59.59% below the high.
€42.89+€0.30 (+0.7%)
Siemens Healthineers AG’s quoted price sits in the upper half of its reported 52-week range, 13.7% below the high.
CN¥178.61-CN¥0.39 (-0.22%)
Shenzhen Mindray Bio-Medical Electronics Co., Ltd.’s quoted price sits in the upper half of its reported 52-week range, 20.44% below the high.
$27.12+$0.09 (+0.33%)
Koninklijke Philips N.V.’s quoted price sits in the lower half of its reported 52-week range, 18.9% below the high.
¥3,478+¥1 (+0.03%)
FUJIFILM Holdings Corporation’s quoted price sits in the upper half of its reported 52-week range, 11.0% below the high.
THE ANALYST VIEW
20 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
Consensus coverage: 7 contributors · Median target $80.00.
Average targets in published notes for each window. These figures use a different sample from the consensus above.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
